These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 11522603)

  • 1. Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells.
    Gessi S; Varani K; Merighi S; Morelli A; Ferrari D; Leung E; Baraldi PG; Spalluto G; Borea PA
    Br J Pharmacol; 2001 Sep; 134(1):116-26. PubMed ID: 11522603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line.
    Merighi S; Varani K; Gessi S; Cattabriga E; Iannotta V; Ulouglu C; Leung E; Borea PA
    Br J Pharmacol; 2001 Nov; 134(6):1215-26. PubMed ID: 11704641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors.
    Varani K; Merighi S; Gessi S; Klotz KN; Leung E; Baraldi PG; Cacciari B; Romagnoli R; Spalluto G; Borea PA
    Mol Pharmacol; 2000 May; 57(5):968-75. PubMed ID: 10779381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A(3) adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study.
    Gessi S; Varani K; Merighi S; Cattabriga E; Iannotta V; Leung E; Baraldi PG; Borea PA
    Mol Pharmacol; 2002 Feb; 61(2):415-24. PubMed ID: 11809867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and preliminary biological evaluation of [3H]-MRE 3008-F20: the first high affinity radioligand antagonist for the human A3 adenosine receptors.
    Baraldi PG; Cacciari B; Romagnoli R; Varani K; Merighi S; Gessi S; Borea PA; Leung E; Hickey SL; Spalluto G
    Bioorg Med Chem Lett; 2000 Feb; 10(3):209-11. PubMed ID: 10698437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261.
    Dionisotti S; Ongini E; Zocchi C; Kull B; Arslan G; Fredholm BB
    Br J Pharmacol; 1997 Jun; 121(3):353-60. PubMed ID: 9179373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of A3 adenosine receptors in human lymphocytes: up-regulation in T cell activation.
    Gessi S; Varani K; Merighi S; Cattabriga E; Avitabile A; Gavioli R; Fortini C; Leung E; Mac Lennan S; Borea PA
    Mol Pharmacol; 2004 Mar; 65(3):711-9. PubMed ID: 14978250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives.
    Gao ZG; Kim SG; Soltysiak KA; Melman N; IJzerman AP; Jacobson KA
    Mol Pharmacol; 2002 Jul; 62(1):81-9. PubMed ID: 12065758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of A2A adenosine receptors in human lymphocyte membranes by [3H]-SCH 58261 binding.
    Varani K; Gessi S; Dalpiaz A; Ongini E; Borea PA
    Br J Pharmacol; 1997 Sep; 122(2):386-92. PubMed ID: 9313951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential allosteric modulation by amiloride analogues of agonist and antagonist binding at A(1) and A(3) adenosine receptors.
    Gao ZG; Melman N; Erdmann A; Kim SG; Müller CE; IJzerman AP; Jacobson KA
    Biochem Pharmacol; 2003 Feb; 65(4):525-34. PubMed ID: 12566079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors.
    Ongini E; Dionisotti S; Gessi S; Irenius E; Fredholm BB
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Jan; 359(1):7-10. PubMed ID: 9933143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors.
    Kull B; Arslan G; Nilsson C; Owman C; Lorenzen A; Schwabe U; Fredholm BB
    Biochem Pharmacol; 1999 Jan; 57(1):65-75. PubMed ID: 9920286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [3H]-SCH 58261 labelling of functional A2A adenosine receptors in human neutrophil membranes.
    Varani K; Gessi S; Dionisotti S; Ongini E; Borea PA
    Br J Pharmacol; 1998 Apr; 123(8):1723-31. PubMed ID: 9605581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding thermodynamics at the human A(3) adenosine receptor.
    Merighi S; Varani K; Gessi S; Klotz KN; Leung E; Baraldi PG; Borea PA
    Biochem Pharmacol; 2002 Jan; 63(2):157-61. PubMed ID: 11841789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes.
    Zocchi C; Ongini E; Ferrara S; Baraldi PG; Dionisotti S
    Br J Pharmacol; 1996 Apr; 117(7):1381-6. PubMed ID: 8730729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells.
    Klotz KN; Hessling J; Hegler J; Owman C; Kull B; Fredholm BB; Lohse MJ
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):1-9. PubMed ID: 9459566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alteration of A(3) adenosine receptors in human neutrophils and low frequency electromagnetic fields.
    Varani K; Gessi S; Merighi S; Iannotta V; Cattabriga E; Pancaldi C; Cadossi R; Borea PA
    Biochem Pharmacol; 2003 Nov; 66(10):1897-906. PubMed ID: 14599547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological analysis of calcium responses mediated by the human A3 adenosine receptor in monocyte-derived dendritic cells and recombinant cells.
    Fossetta J; Jackson J; Deno G; Fan X; Du XK; Bober L; Soudé-Bermejo A; de Bouteiller O; Caux C; Lunn C; Lundell D; Palmer RK
    Mol Pharmacol; 2003 Feb; 63(2):342-50. PubMed ID: 12527805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes.
    Kim YC; de Zwart M; Chang L; Moro S; von Frijtag Drabbe Künzel JK; Melman N; IJzerman AP; Jacobson KA
    J Med Chem; 1998 Jul; 41(15):2835-45. PubMed ID: 9667972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists.
    Yang M; Soohoo D; Soelaiman S; Kalla R; Zablocki J; Chu N; Leung K; Yao L; Diamond I; Belardinelli L; Shryock JC
    Naunyn Schmiedebergs Arch Pharmacol; 2007 Apr; 375(2):133-44. PubMed ID: 17310264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.